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OBJECTIVE—The objectives of the study were to evaluate
retrograde axonal transport of vascular endothelial growth factor
A (VEGF-A) protein to sensory neurons after intramuscular
administration of an engineered zinc ﬁnger protein activator of
endogenous VEGF-A (VZ434) in an experimental model of
diabetes, and to characterize the VEGF-A target neurons.
RESEARCH DESIGN AND METHODS—We compared the
expression of VEGF-A in lumbar (L)4/5 dorsal root ganglia (DRG)
of control rats and VZ434-treated and untreated streptozotocin
(STZ)-induced diabetic rats. In addition, axonal transport of
VEGF-A, activation of signal transduction pathways in the DRG,
and mechanical sensitivity were assessed.
RESULTS—VEGF-A immunoreactivity (IR) was detected in
small- to medium-diameter neurons in DRG of control rats.
Fewer VEGF-A-IR neurons were observed in DRG from STZ-
induced diabetic rats; this decrease was conﬁrmed and quantiﬁed
by Western blotting. VZ434 administration resulted in a signif-
icant increase in VEGF-A protein expression in ipsilateral DRG,
24 h after injection. VEGF-A was axonally transported to the
DRG via the sciatic nerve. VZ434 administration resulted in
signiﬁcant activation of AKT in the ipsilateral DRG by 48 h that
was sustained for 1 week after injection. VZ434 protected
against mechanical allodynia 8 weeks after STZ injection.
CONCLUSIONS—Intramuscular administration of VZ434 in-
creases VEGF-A protein levels in L4/5 DRG, correcting the deﬁcit
observed after induction of diabetes, and protects against me-
chanical allodynia. Elevated VEGF-A levels result from retro-
grade axonal transport and are associated with altered signal
transduction, via the phosphatidylinositol 3-kinase pathway.
These data support a neuroprotective role for VEGF-A in the
therapeutic actions of VZ434 and suggest a mechanism by
which VEGF-A exerts this activity. Diabetes 59:509–518, 2010
T
he vascular endothelial growth factor (VEGF)
family consists of seven secreted glycoproteins,
named VEGF-A to -F and placental growth
factor. The prototypic VEGF family member,
VEGF-A, was ﬁrst demonstrated to enhance vascular per-
meability and promote the proliferation, migration, and
survival of endothelial cells leading to increased angiogen-
esis and tissue perfusion (1). In addition to its angiogenic
properties, both neurotrophic and neuroprotective func-
tions for VEGF-A have been described in both sensory
(2–6) and motor (7) neurons.
The VEGFs bind to, and signal through, speciﬁc re-
ceptor tyrosine kinases: VEGF receptor (VEGFR)-1 (Flt-1);
VEGFR-2 (KDR; Flk-1); and the neuropilin receptors 1 and
2 (8,9), as well as via interaction with heparin sulfate
proteoglycans (10). VEGF-A can activate both the mitogen-
activated protein kinases (MAPKs) and the phosphatidylino-
sitol 3-kinase (PI3-K) signal transduction pathways (11), and
both of these pathways have been implicated as mediators of
the phenotypic abnormalities observed in sensory neurons
during the development of diabetic neuropathy (12–15).
VEGF-A mRNA is alternatively spliced to express three
major protein isoforms, VEGF-A121, VEGF-A165, and VEGF-
A189. Both experimental and clinical studies have indicated
improvements in the signs and symptoms of sensory
diabetic neuropathy after intramuscular injection of a
plasmid DNA encoding a single isoform of VEGF-A,
VEGF165-A (16–18). However, several preclinical studies
suggest that the combination of all three VEGF-A isoforms
may provide more potent biological activity (19–21).
Given the importance of all VEGF-A isoforms, we have
chosen to investigate an alternative strategy for the ther-
apeutic application of this growth factor, namely, the
activation of the endogenous VEGF-A gene through the
action of an engineered zinc ﬁnger protein–transcription
factor (ZFP-TF). Transfection of plasmid DNA encoding
the VEGF-A–activating ZFP-TF, VZ434, results in the
expression of all three major isoforms of VEGF-A in their
correct proportions (22). Moreover, it has also been dem-
onstrated that intramuscular administration of VZ434
drives therapeutic angiogenesis (23) and provides signiﬁ-
cant, and dose-related, protection of both motor and
sensory nerve conduction velocity (NCV) deﬁcits in strep-
tozotocin (STZ)-induced diabetic rats (24). ZFP-TF–driven
VEGF-A activation thus has both neuroprotective and
angiogenic effects that could contribute directly (or indi-
rectly) to improvements in NCV.
To begin to investigate the mechanism(s) by which
VEGF-A affects nerve function, we have examined retro-
grade axonal transport of VEGF-A protein after intramus-
cular administration of VZ434 in the rat STZ-induced
model of diabetic neuropathy. We show that VEGF-A is
normally expressed in small- to medium-diameter sensory
neurons of the dorsal root ganglia (DRG), and is down-
regulated in diabetes. However, VEGF-A protein levels can
be normalized by intramuscular injection of VZ434.
Plasmid DNA encoding VZ434 is found in the muscle but
not in the DRG, whereas VEGF-A protein is shown to
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In addition, we demonstrate sustained activation of AKT in
the DRG, demonstrating a functional consequence to the
increased VEGF-A levels in this tissue, which may underlie
the neuroprotective effect of VZ434-mediated VEGF-A
activation in STZ-induced diabetic rats.
RESEARCH DESIGN AND METHODS
Induction of diabetes. All studies and procedures were licensed under the
U.K. Animals (Scientiﬁc Procedures) Act 1986. Diabetes was induced in adult
male Wistar rats (250–300 g; Charles River, Margate, U.K.) via intraperitoneal
injection of freshly dissolved STZ (55 mg/kg in sterile saline), administered
after an overnight fast. Diabetes was veriﬁed 3 days after STZ injection using
a strip-operated reﬂectance photometer (OptimumPlus; MediSense, Whitney,
U.K.) to measure the animal’s tail vein blood glucose levels. Rats with blood
glucose less than 15 mmol/l were excluded from the study. Age- and
weight-matched rats were used as nondiabetic controls. The VEGF-A activat-
ing ZFP-TF VZ434 has previously been described (22). Plasmids were
formulated at a concentration of 2 mg/ml in 5% poloxamer 188 (BASF,
Florham, NJ), 150 mmol/l NaCl, and 2 mmol/l Tris (pH 8.0; Sangamo
BioSciences).
Study design. Three weeks after induction of diabetes, control and STZ-
induced diabetic rats were anesthetized with isoﬂurane (2% in oxygen) and
were either injected with a total of 250 gV Z 434 at two sites in their left
gastrocnemius/soleus muscle, or left untreated.
After injection of VZ434, additional groups of treated and untreated
diabetic rats also had their left sciatic nerve exposed and ligated with
polypropylene monoﬁlament nonabsorbable sutures (Prolene; Ethicon) at
mid-thigh level, proximal to the site of injection. The wound was closed and
animals recovered under observation. Rats were killed at selected time points
after injection with VZ434 (1, 2, 7, and 14 days), or for the sciatic nerve
ligation studies at 1 day after ligation.
Ipsilateral and contralateral muscle, sciatic nerves, and lumbar (L)4/5 DRG
were removed. Tissue designated for Western blot analysis was snap frozen in
liquid nitrogen and stored at 40°C until processing. Sciatic nerve and DRG
samples destined for immunohistochemical studies were postﬁxed in 4%
paraformaldehyde overnight at 4°C, then cryoprotected in 30% sucrose in 0.1
M phosphate buffer for 24 h at 4°C. Tissues were then frozen in OCT
embedding medium (VWR, Lutterworth, U.K.) and stored at 40°C until
processing.
For sensory testing experiments, STZ-induced diabetic rats were either
untreated or treated with 250 gV Z 434 at 4, 6, and 8 weeks after STZ
injection, in two sites in their left gastrocnemius/soleus muscle (n  6–10 per
group). Behavioral responses of STZ-induced diabetic rats and age-matched
control rats to tactile stimulation were measured at baseline (before STZ
injection), and at 4, 8, and 12 weeks after STZ injection.
Western blotting. Western blotting was conducted as previously described
(25). Blots were incubated overnight at 4°C with primary antibodies: anti–
VEGF-A (1:500; Santa Cruz Biotechnology), anti–total extracellular signal–
related kinase (ERK; 1:2000; Cell Signaling Technology, Danvers, MA), anti–
phospho AKT and anti–total AKT (1:2000; Cell Signaling Technology), and
anti–III-tubulin (1:1,000; Sigma). Blots were washed and incubated in horse-
radish peroxidase–linked anti-rabbit IgG or anti-mouse IgG (1:2000; Cell
Signaling Technology) for1ha troom temperature. Protein bands were
visualized using LumiGLO and Peroxidase Reagent (Cell Signaling Technol-
ogy). The ﬁlms were scanned, and the total pixel intensity for each band was
calculated using SigmaScan Pro5 software (SPSS, Chicago, IL). Graphs and
statistical analyses were prepared using GraphPad PRISM 4 software. Data
were analyzed using either one-way ANOVA followed by either the Dunnett
post hoc test, Student paired t test, or Student one-sample t test as appropri-
ate. Data are expressed as mean  SD.
Immunohistochemistry. Longitudinal sections (12-m) of sciatic nerve or
L4/5 DRG were thaw-mounted onto Superfrost Plus Slides (VWR). Sections
were washed with PBS, and then incubated in blocking buffer (10% normal
donkey serum, 0.2% Triton-X100 in PBS) for 1 h at room temperature. Slides
were incubated overnight at either 4°C or room temperature with primary
antibodies (in blocking buffer): anti–VEGF-A (1:500; Santa Cruz Biotechnol-
ogy), anti–calcitonin gene-related peptide (CGRP; 1:500; Sigma), anti–neuro-
ﬁlament 200 (NF200; 1:400; Chemicon), anti-S100 (1:500; Sigma), or anti–
phospho (p) AKT (1:100; Promega). Slides were washed and then incubated
with either cyanin 3–conjugated donkey anti-rabbit and/or ﬂuorescein isothio-
cyanate–conjugated donkey anti-mouse IgG as appropriate (1:200; Jackson
ImmunoResearch) for1ha troom temperature. In addition some slides were
colabeled with ﬂuorescein isothiocyanate–conjugated isolectin B4 from Grif-
fonia simplicifolia (20 g/ml; Vector Labs, Peterborough, U.K.). Sections
were mounted in Vectorshield containing DAPI (Vector Labs). Immunoﬂuo-
rescence was visualized using a Leica MPS60 DMR ﬂuorescent microscope.
Digital images were acquired using WASABI software (Hamamatsu Photonics,
Herts, U.K.) and processed using Adobe Photoshop CS (Adobe Systems).
Image analysis. The threshold for high VEGF-A immunoreactivity (IR) was
determined by calculating the mean staining intensity of four neurons per
animal that were deemed to be positively stained (SigmaScan Pro). This mean
intensity was then taken as the threshold value to determine the percentage of
VEGF-A-IR neuronal proﬁles. All neuronal proﬁles were traced and mean
VEGF-A-IR and Feret diameter of each proﬁle were automatically calculated
(SigmaScan Pro) and data were used for cell size distribution analysis. Cell
proﬁles from four randomly selected sections (each 100-m apart) of ipsilat-
eral and contralateral L4/5 DRG (processed on the same slide) from four
animals in each treatment group were measured. The method of recursive
translation was applied to these results to correct for overestimation of both
large and small-diameter cell proﬁles (26).
Taqman and quantitative RT-PCR. VZ434 plasmid DNA levels were
measured in duplicate reactions containing 100 ng of DNA and TaqMan
Universal PCR Mix (Applied Biosystems, Foster City, CA). Reactions were
analyzed using an ABI 7300 Real Time PCR System (Applied Biosystems).
Plasmid copy numbers (PCNs) were determined from a standard curve
prepared from a 10-fold serial dilution of VZ434. The background PCN level
was determined from the mean of VZ434 levels in tissues from the right
(contralateral) side plus 2 SD.
Testing of mechanical thresholds. At 1 week prior to, and at 4, 8, and 12
weeks after induction of diabetes, the behavioral response to mechanical
stimulation of the hind paw was assessed using a dynamic plantar aesthesi-
ometer (Ugo Basile, Comerio, Italy). Paw withdrawal responses were mea-
sured in both right and left hind paws in all animals, and are reported as the
mean of three measurements per paw, taken at least 10 min apart. Testing was
TABLE 1
Blood glucose and body weight measurements






1 Diabetic  VZ  434 24 h 26.0  1.7 324  6 334  48
2 Diabetic  VZ  434 48 h 25.9  1.6 280  16 229  18
3 Diabetic  VZ  434 1 week 20.8  4.2 317  10 335  48
4 Diabetic  VZ  434 2 weeks 23.3  4.3 326  16 376  78
5 Control 7.9  0.4 332  18 491  5
Experiment 2
1 Diabetic  VZ  434 24 h 19.1  2 274  14 257  20
2 Diabetic  VZ  434  sciatic ligature 24 h 21.1  2.1 287  24 271  25
3 Diabetic  ligature 24 h 18.5  2.3 278  15 247  13
4 Diabetic untreated 22.6  5.7 280  16 270  28
5 Control untreated 8  1.4 272  16 352  26
Data are means  SD (n  4 per group). Two studies were performed in STZ-induced diabetic rats: experiment 1, time course study; and
experiment 2, axonal transport study. Final blood glucose levels and start and end body weights for all groups are shown.
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day of testing. The assessor was blinded to the VZ434-treated and untreated
STZ groups.
RESULTS
VEGF-A is downregulated in the DRG of STZ-induced
diabetic rats compared with control rats. Using West-
ern blot and immunocytochemical analysis, we compared
the expression of VEGF-A in L4/5 DRG of control rats and
rats 3 weeks after induction of STZ-induced diabetes (see
Table 1 for details of blood glucose levels and body
weight). VEGF-A levels were signiﬁcantly reduced in L4/5
DRG from rats 3 weeks after STZ injection (control rats:
16.6  3.2 versus diabetic rats: 3.9  1.6 arbitrary units
[AU], P  0.0001, Fig. 1A and B).
VEGF-A-IR was clearly detected within the cytoplasm of
a population of small- to medium-diameter sensory neu-
rons in the DRG of control rats (Fig. 1C, arrows) and also
in motor neurons in the ventral horn of the spinal cord
(data not shown). Fewer VEGF-A-IR neurons were ob-
served in DRG from STZ-induced diabetic rats (Fig. 1D and
E, control rats: 6.5  2.7% VEGF-A-IR neurons versus
diabetic rat: 1.9  2.2% VEGF-A-IR neurons; P  0.01).
Immunoﬂuorescence was abolished by omission of the
primary antibody, indicating the VEGF-A-IR to be primary-
antibody speciﬁc (data not shown).
Intramuscular administration of VZ434 increases
VEGF-A in the ipsilateral DRG of STZ-induced dia-
betic rats. A single intramuscular dose of the VEGF-A–
activating zinc ﬁnger protein transcription factor VZ434
resulted in a rapid and signiﬁcant increase in VEGF-A
protein expression in ipsilateral L4/5 DRG (Fig. 2). This
increase was evident as early as 24 h after injection (left:
5.2  1.2 versus right: 1.0  0.2 AU, P  0.05); VEGF-A
levels were normalized by 1 week after injection (Fig. 2A
and B). VEGF-A-IR was detected in contralateral (Fig. 2C)
and ipsilateral (Fig. 2D) L4/5 DRG within a population of
small- to medium-diameter sensory neurons (Fig. 2C and
D; arrows). Intramuscular treatment with VZ434 gener-
ated a signiﬁcant increase in VEGF-IR in small-diameter
neurons in the ipsilateral compared with contralateral
DRG. VEGF-A-IR was signiﬁcantly elevated in neurons
with diameters between 18.75 and 22.5 m compared with
contralateral DRG (Fig. 2E and F, P  0.05).
To further characterize the population of VEGF-A-IR
neurons in ipsilateral L4/5 DRG, we performed dual immu-
noﬂuorescence experiments with anti–VEGF-A (Fig. 3A, C,
and E) and three neurochemical phenotypic markers:
CGRP (Fig. 3B), to label small-diameter nociceptive pep-
tidergic neurons; isolectin B4 (IB4; Fig. 3D), a marker
for nonpeptidergic small-diameter sensory neurons; and
NF200 (Fig. 3F), a heavy chain neuroﬁlament protein that
labels predominantly large-diameter proprioceptive and
mechanoreceptive sensory neurons. VEGF-A-IR was ob-
served predominantly in the CGRP-IR and IB4-positive
populations, whereas very few VEGF-A-IR neurons colo-
calized with NF200-IR (Fig. 3E and F).
Plasmid DNA encoding VZ434 is not transported to,
or transcribed within, the DRG. To investigate the
mechanism by which intramuscular VZ434 normalized
VEGF levels in the DRG of diabetic rats, we measured
VZ434 DNA in ipsilateral and contralateral muscle and
L4/5 DRG samples from diabetic rats, 24 h after a single
intramuscular dose of VZ434 (Fig. 4).
The background PCN of VZ434 was set at 2,700
(derived from mean plus 2 SD from contralateral tissue
FIG. 1. VEGF-A is downregulated in the DRG of STZ-induced diabetic
rats. Western blot analysis of VEGF-A levels in pooled L4/5 DRG
obtained from control (C) rats or diabetic rats 3 weeks after STZ
injection (D) show a dramatic decrease in VEGF-A in diabetes (A).
Densitometric analysis of VEGF-A protein levels (normalized to
total ERK to correct for protein loading) shows a signiﬁcant de-
crease after STZ injection (***P < 0.0001, t test, n  5 per group, B).
Representative micrographs show that VEGF-A-IR is present in
sensory neurons in L4/5 DRG. A population of small- to medium-
diameter neurons in DRG from control rat DRG shows VEGF-A-IR
(arrows, C and E). Fewer VEGF-A-IR neurons were observed in DRG
obtained from STZ-induced diabetic rats (D and E). Data for
individual animals (n  4 per group, **P < 0.01, t test) are shown as
circles and the mean value is shown as a horizontal bar (E). Scale
bar, 50 m.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 511FIG. 2. Intramuscular administration of VZ434 increases VEGF-A in the ipsilateral DRG of STZ-induced diabetic rats. Diabetic rats (3
weeks after STZ injection) received two intramuscular injections of the VEGF-A–activating zinc ﬁnger protein-transcription factor VZ434
(250 g total) into the gastrocnemius muscle and were killed at the indicated time points after injection (n  4 per time point). VEGF-A
levels in right (uninjected, contralateral limb) and left (injected, ipsilateral limb) were assessed using Western blotting (A) and quantiﬁed
using densitometry (normalized to total AKT to correct for protein loading; B). Intramuscular VZ434 caused a rapid and signiﬁcant
increase in VEGF-A protein expression in ipsilateral L4/5 DRG compared with contralateral by 24 h after injection (A and B, *P < 0.05, **P <
0.01 paired t test). Increased VEGF-A-IR (C and D, arrows) was clearly detected within a population of small- to medium-diameter sensory
neurons in the ipsilateral DRG (left, D) compared with the contralateral DRG (right, C). Cell size distribution analysis shows a signiﬁcant
increase in VEGF-A-IR neurons in small-diameter neurons in the ipsilateral (F,* P < 0.05, ANOVA) compared with contralateral DRG (E).
Scale bar, 50 m.
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copies of VZ434 than contralateral muscle (mean values:
left 407168 vs. right 993 copies/100 ng DNA, P  0.05,
Mann-Whitney U test, Fig. 4). No signiﬁcant left-right
tissue difference in VZ434 levels in DRG samples was
observed (Fig. 4), suggesting that plasmid uptake is re-
stricted to the site of injection, resulting in upregulation of
VEGF-A in the muscle, consistent with previous observa-
tions (27). Importantly, the results demonstrate that ax-
onal transport of VZ434 plasmid is not responsible for
the increased VEGF-A levels in the DRG.
VEGF-A undergoes axonal transport in sciatic nerve
in vivo. Axonal transport of VEGF-A protein in the sciatic
nerve of diabetic rats was assessed using immunocyto-
chemistry and Western blotting techniques (Fig. 5). Liga-
tion of the sciatic nerve of diabetic rats injected distally
with VZ434 caused an increase in VEGF-A-IR both
proximal and, notably, distal to the ligature site (Fig. 5A).
VEGF-A-IR was clearly observed in axonal proﬁles; a
region is highlighted and shown as inset (Fig. 5A and B,
arrows). VEGF-A-IR did not colocalize with S100-IR
Schwann cells (Fig. 5C).
Ligation of the sciatic nerve of untreated diabetic rats
showed very little axonal accumulation of VEGF-A-IR (Fig.
5E), restricted to the regions of nerve immediately adjacent
to the ligature, a marked contrast to the wide distribution of
VEGF-A-IR in the VZ434-injected rats, particularly through-
out the distal nerve (Fig. 5A, arrows). VEGF-A-IR was absent
from the contralateral nerve (Fig. 5D).
Ligation of the sciatic nerve of control rats (nondia-
betic), either injected with VZ434 (Fig. 5G) or left
untreated (Fig. 5F), revealed an accumulation of VEGF-
A-IR proximal and distal to the ligature site.
These observations were conﬁrmed by Western blot
analysis of VEGF-A protein levels in nerve segments taken
proximal and distal to the ligature (schematic diagram
illustrated in Fig. 5H). Protein levels were quantiﬁed by
densitometric analysis. Increased VEGF-A was observed
particularly in all distal segments and segments immedi-
ately proximal to the ligature site in diabetic rats injected
with VZ434 (Fig. 5I). In contrast, sciatic nerve samples
prepared from control rats injected with VZ434 showed
a more even distribution of VEGF-A throughout the whole
nerve (Fig. 5J), with the greatest accumulation observed in
the proximal segment adjacent to the ligature (Fig. 5J).
Together these data demonstrate that VEGF-A undergoes
axonal transport to the DRG and that intramuscular ad-
ministration of VZ434 is sufﬁcient to overcome the deﬁcit
in VEGF-A levels observed in this tissue in this STZ model
of diabetes.
Ligation of the sciatic nerve reduced the VZ434-
mediated increase in VEGF-A in the DRG. Diabetes
was associated with a signiﬁcant decrease in basal
VEGF-A protein levels in the DRG (Fig. 1B and supplemen-
tary Fig. 1A and B, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db08-
1526/DC1), and VZ434 administration restored VEGF-A
to control levels (supplementary Fig. 1A and B). However,
this increase was markedly reduced by ligation of the
sciatic nerve in three of ﬁve animals tested (mean change
across all ﬁve animals was not signiﬁcant) (supplementary
Fig. 1A and B). Taken together with the absence of
plasmid DNA encoding VZ434 in the DRG, these data
suggest that the observed normalization of VEGF-A levels
in the DRG after VZ434 treatment occurs via retrograde
axonal transport of VEGF-A protein in the sciatic nerve.
VEGF-A accumulation in the DRG is associated with
activation of the PI3-K pathway. To analyze the func-
tional consequences of elevated VEGF-A levels in the
DRG, we investigated intracellular signaling pathways
potentially responsible for the VEGF-A–mediated neuro-
protective effects in diabetic neuropathy. Speciﬁcally, we
investigated activation of p38 MAPK, ERK1/2, and PI3-K
pathways using phospho-speciﬁc antibodies. Neither the
levels nor the phosphorylation status of the MAPKs p38
and ERK1/2 was signiﬁcantly altered in the DRG of
VZ434-injected diabetic rats at any time point studied
FIG. 3. Phenotypic characterization of VEGF-A-IR neurons in L4/5 DRG
of diabetic rats after VZ434. Representative micrographs show that
VEGF-A-IR is present in sensory neurons in L4/5 DRG. Sections have
been dual labeled with (A, C, and E) anti–VEGF-A and anti-CGRP (B);
IB4 (D); and anti-NF200 (F). A large proportion of neurons that
express VEGF-A-IR (A and C, arrows) coexpress the phenotypic mark-
ers CGRP (B, arrows) and IB4 (D, arrows). Note, very few VEGF-A-IR
neurons colocalize with NF200 (E and F, asterisk). Scale bar, 50 m.
FIG. 4. Expression of VZ434 DNA plasmid copy number in ipsilateral
and contralateral tissues. At 24 h after unilateral intramuscular injec-
tion of VZ434 (250 g), tissues were harvested and DNA was ex-
tracted. The background PCN of VZ434 was set at 2,700 (derived from
mean  2 SD from contralateral tissue samples). Data from individual
animals are shown as circles, with the mean as a horizontal bar (n  8
for muscle and n  4 for DRG). Ipsilateral muscle contained signiﬁ-
cantly more copies of VZ434 per 100 ng DNA than contralateral
muscle, whereas there was no signiﬁcant left-right tissue difference in
VZ434 in DRG (*P < 0.05, Mann-Whitney U test).
E.J. PAWSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 513FIG. 5. VEGF-A undergoes axonal transport in the sciatic nerve in vivo. Adult rats received a unilateral sciatic nerve ligature at mid-thigh level,
proximal to the site of VZ434 injection (250 g, intramuscularly) Longitudinal sections of sciatic nerve, 24 h after ligation, were immunostained
for VEGF-A (red) and S100 to label Schwann cells (green; A–G). VEGF-A-IR can clearly be seen to accumulate within axons (A, arrows) at the
ligature site, proximal and distal to the ligature site, indicating bidirectional axonal transport. A region highlighted by a rectangle in (A) is shown
at increased magniﬁcation in (B). VEGF-A-IR was restricted to axons and not Schwann cells (B and C). Little VEGF-A-IR was observed in
unligated contralateral nerve (D) or untreated ligated nerve (E). In contrast, VEGF-IR accumulated both proximal and distal to ligatures in both
untreated (F) or treated (G) control rats. Scale bars  1 mm. Ligated sciatic nerves from VZ434-injected STZ-induced diabetic rats (I)o r
control rats (J) were cut into 5-mm segments proximal and distal to the ligature and samples processed for Western blotting to assess VEGF-A
levels (see schematic diagram, H). VEGF-A accumulated both proximal and particularly distal to the ligature in VZ434-injected diabetic rats (I).
Samples prepared from control rats injected with VZ434 showed the greatest accumulation of VEGF in proximal samples (J). Data for individual
animals are shown as circles; the mean value is shown as a horizontal bar (I and J). (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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contralateral 1.0  0.73 AU, P 	 0.05, n  4; ERK1/2:
ipsilateral 1.56  0.25 versus contralateral 1.0  0.34 AU,
P 	 0.05, n  4).
In contrast, an increase in AKT phosphorylation was
observed in the ipsilateral L4/5 DRG 48 h after VZ434
injection (left: 5.4  2.6 versus right: 1.0  0.4 AU, P 
0.05, n  4), and activation was maintained for 1 week
(left: 2.0  0.6 versus right: 1.0  0.6 AU, P  0.01, n  4;
Fig. 6A and B). This increase in pAKT in the ipsilateral
compared with contralateral DRG was conﬁrmed using
immunocytochemical analysis (Fig. 6C–F). Ipsilateral and
contralateral DRG were colabeled with antibodies against
VEGF-A (Fig. 6C and E) and pAKT (Fig. 6D and F). A
threefold increase in neurons expressing pAKT-IR was
observed in the ipsilateral DRG compared with the con-
tralateral DRG (Fig. 6D and F arrows; left: 10% pAKT-IR
neurons versus right 3% pAKT-IR neurons, P  0.05).
Furthermore, of the pAKT-IR neurons 61% coexpressed
VEGF-IR and of the VEGF-IR neurons 85% coexpressed
pAKT-IR. Because pAKT-IR is observed in a greater num-
ber of neurons than those possessing VEGF-IR, this may
suggest a paracrine action of VZ434-generated and
-transported VEGF-A within the DRG.
Intramuscular administration of VZ434 protects
against mechanical allodynia. To determine whether
the VZ434-mediated increase of VEGF-A in small- to
medium-diameter neurons has protective effects in exper-
imental diabetic neuropathy, we investigated the functional
efﬁcacy of VZ434 on the development of mechanical hyper-
sensitivity and/or hyposensitivity in STZ-induced diabetic
rats (Fig. 7).
Eight weeks after the induction of diabetes, hind paw
thresholds to mechanical stimulation were signiﬁcantly
reduced compared with pre-STZ thresholds (Fig. 7A) and
age-matched control rats (Fig. 7B). Similarly, paw with-
drawal response thresholds from the contralateral hind
limb of STZ-induced diabetic rats treated with VZ434
were reduced compared with both pre-STZ values (Fig.
7A) and age-matched control rats (Fig. 7C). However,
VZ434 treatments provided signiﬁcant protection against
mechanical allodynia in the left hind paw 8 weeks after
STZ injection (Fig. 7A and D). This suggests that the
VZ434-mediated increase of VEGF-A in the DRG protects
against the mechanical hypersensitivity observed in STZ-
induced diabetes.
DISCUSSION
This study demonstrates that VEGF-A protein levels in the
DRG are reduced in STZ-induced diabetic rats at early
stages of the disease (3 weeks after STZ injection). This
deﬁcit was corrected by intramuscular administration of
VZ434, a plasmid that encodes a zinc ﬁnger protein-
transcription factor capable of simulating endogenous
production of VEGF-A. There was no evidence of VZ434
plasmid DNA being transported to, or transcribed within,
the DRG, rather VEGF-A protein was axonally transported
to sensory neurons in ipsilateral L4/5 DRG 24 h after
injection, and was associated with altered signal transduc-
tion, via the PI3-K pathway. Treatment with VZ434
provided unilateral protection against mechanical allo-
dynia 8 weeks after STZ injection.
VEGF-A was localized to small- to medium-diameter
FIG. 6. AKT is phosphorylated in ipsilateral L4/5 DRG after VZ434 injection. Diabetic rats (3 weeks after STZ injection) treated with VZ434
were killed at the indicated time points after injection (24 h, 48 h, 1 week, 2 weeks; n  4 per time point). Phosphorylated (p-AKT) and total
(t-AKT) AKT levels in right (uninjected, contralateral limb) and left (injected, ipsilateral limb) DRG were assessed using Western blotting (A)
and quantiﬁed using densitometry (B). Intramuscular administration of VZ434 caused a rapid and signiﬁcant ipsilateral increase in pAKT levels
in L4/5 DRG (A and B) by 48 h after injection (*P < 0.05) and remained signiﬁcantly elevated for 1 week (***P < 0.001). Immunocytochemical
analysis with antibodies against VEGF-A and pAKT showed colabeling of VEGF-A-IR (C) and pAKT (D) neurons in the DRG (arrows), however,
pAKT-IR neurons that did not colocalize with VEGF-IR neurons were also observed (asterisk). Reduced pAKT-IR was observed in contralateral
DRG (E). Scale bar, 50 m.
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previous studies (2,5), and was downregulated 3 weeks
after induction of diabetes. The time course of VEGF-A
expression in the DRG after induction of diabetes has not
been systematically characterized to date, and evidence
suggests a dynamic regulation over the course of the
disease. VEGF-A-IR has been reported to be upregulated in
the DRG 12 weeks after STZ injection in mice (28),
however we found no change in VEGF-A protein levels 12
weeks after STZ injection in rats (data not shown).
Receptors for VEGF-A have previously been character-
ized in sensory neurons (8,9,29). Neurons appear to lack
VEGFR-1, which is largely expressed by endothelial cells
(30,31). Conﬂicting evidence exists about the neuronal
expression of VEGFR-2 in sensory neurons. Sondell et al.
(2,5,6) describe a postnatal decrease in the percentage of
VEGFR-2-IR neurons in the DRG, with less than 10% of
sensory neurons expressing VEGFR-2 in adult mouse
DRG. These VEGFR-2–positive neurons were of the large-
diameter RT97-positive population and the small-diameter
CGRP-IR population; no IB4-positive neurons expressed
VEGFR-2 (6). In contrast, other groups did not detect
VEGFR-2 in sensory neurons (31). Neuropilin-1 is highly
expressed in sensory neurons (6,31,32); however, the
neuropilin receptors lack deﬁned signaling motifs and
appear to act as a coreceptor for VEGFR-2.
A decrease in VEGF-A in sensory neurons may be a
functional defect associated with the pathogenesis of
diabetic neuropathy. Indeed, clinical studies by Quattrini
et al. identiﬁed a signiﬁcant reduction in VEGF-A levels
and endothelial cell dysfunction, and a loss in intraepider-
mal nerve ﬁbers, in skin biopsy samples taken from
patients with increasing severity of diabetic neuropathy
(33). Diabetic neuropathy is a heterogeneous disease with
a widely varying pathology including a neurotrophin deﬁ-
cit. A deﬁcit in nerve growth factor (NGF) expression by
sensory neuron targets and retrograde transport to the
DRG is well established in experimental diabetic neurop-
athy (34–36). Indeed, the reduced availability of NGF in
experimental diabetic neuropathy provided the rationale
of NGF administration as a potential treatment for the
disease, and normalizes key molecular and functional
aspects of the neuropathy (37,38). It has not been estab-
lished whether glial cell–derived neurotrophic factor pro-
duction is similarly impaired in diabetes, however therapy
with exogenous glial cell–derived neurotrophic factor in
experimental diabetes normalized cutaneous innervation
in STZ-induced diabetic mice (39,40). VEGF-A has demon-
strated neurotrophic functions in both central and periph-
eral neurons (4–6), and a number of studies have
demonstrated a neuroprotective role for VEGF-A in exper-
imental diabetic neuropathy after administration of
VEGF-A by gene transfer (16,17,24). Due to the paradox
surrounding VEGF-A in relation to both macrovascular
and microvascular complications in diabetes, targeted
local delivery of VEGF-A is crucial for the treatment of
diabetic neuropathy.
We have previously demonstrated that unilateral intra-
FIG. 7. VZ434 protects against mechanical hyperalgesia. Sensory testing was conducted prior to treatment (baseline measures) and at 4, 8, and
12 weeks after STZ injection. VZ434-treated rats received unilateral intramuscular injections at 4, 6, and 8 weeks after STZ injection. At the
4- and 8-week time points, mechanical thresholds were assessed 3 days after VZ434. At 8 weeks after STZ injection, a signiﬁcant decrease in the
paw withdrawal force (PWF) was observed in STZ-induced diabetic rats and in the contralateral hind paw of VZ434-treated STZ-induced diabetic
rats compared with their baseline measures (A, mean  SD, *P < 0.05, n  7–9, two-way ANOVA, Bonferroni multiple comparison test). At 8
weeks, STZ-induced diabetic rats (B) and the contralateral hind paw of VZ434-treated rats (C) compared with nondiabetic controls (B and C).
VZ434 treatment (D) provided signiﬁcant protection against this allodynia in the ipsilateral limb (B–D, data shown for individual animals *P <
0.05; **P < 0.01, n  7–9, one-way ANOVA, Dunnett post hoc test).
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motor NCV deﬁcits in the ipsilateral sciatic nerve of
STZ-induced diabetic rats (24), and suggested a direct
neuroprotective role of VEGF-A in experimental diabetic
neuropathy. In this current study, we extend these obser-
vations to demonstrate a further neuroprotective effect of
VZ434, namely protection against mechanical allodynia.
After intramuscular VZ434 there is a correction in retro-
grade axonal transport of VEGF-A in the sciatic nerve to
the DRG. As with the NCV change, this effect was re-
stricted to the neurons ipsilateral to the injection. We also
observed accumulation of VEGF-A proximal to the liga-
ture, in accordance with other studies showing VEGF
axonal transport to be bidirectional (6,16,41).
The mechanism of uptake of VEGF-A by sensory affer-
ent terminals present in the gastrocnemius muscle is
unclear. NGF release from cultured smooth muscle cells is
elevated in the presence of contractile stimuli (42). It
is feasible that, in our study, VEGF-A release from the
injected skeletal muscle occurs in this way, aided by the
everyday movement of the rats. We postulate that VEGF-A
uptake occurs via binding to VEGFR-2; it is well estab-
lished that upon ligand binding VEGFR-2 is internalized
with caveolin-1 and dynamin-2 and undergoes intracellular
trafﬁcking and nuclear localization, via microtubules and
the endocytic pathway (43–47).
VZ434-induced VEGF-A activates the cytoplasmic Ser/
Thr kinase AKT in L4/5 DRG ipsilateral to the VZ434
injection. The downstream targets of VEGF-A/AKT activa-
tion are currently under investigation. The PI3-K pathway
is activated by many growth factors including IGFs, insu-
lin, and NT-3 in sensory neurons (48–51), all of which are
reduced in diabetic neuropathy (13,52,53). Furthermore,
VEGF-A increases pAKT in primary cultures of dissociated
rat sensory neurons (data not shown). A study using the
PI3-K inhibitor, LY294002, on mice DRG explants impli-
cated this pathway in sensory neuron survival, as
LY294002 caused a dose-dependent cell death (54). PI3-K
promotes neuronal cell survival by modulation of Bcl-2
and thus mitochondria function, and regulates energy
metabolism in sensory neurons. In addition, activation of
the PI3-K/AKT pathway increases axonal caliber and ter-
minal branching of sensory neurons in vitro (55) and thus
plays an important role in axon morphological dif-
ferentiation.
Because phosphorylation of AKT occurs in a greater
number of neurons than those possessing VEGF-A-IR after
VZ434 administration, this may support the notion of
both an autocrine and paracrine action of transported
VEGF-A within the DRG. This could also explain how
expression of VEGF-A, by small- to medium-diameter
neurons in the DRG, may ameliorate the NCV deﬁcits
measured in large-diameter myelinated axons in diabetic
neuropathy (24), as increased pAKT-IR is observed in all
populations of sensory neurons, however further experi-
ments would be necessary to conﬁrm this. Alternatively,
NCV deﬁcits may be ameliorated by another, as yet
unidentiﬁed, mechanism such as restoration of nerve blood
ﬂow.
Our current work suggests that VEGF-A is able to
modulate the PI3-K signaling cascade in the L4/5 DRG,
which may underlie the neuroprotective action of VZ434
in the management of diabetic neuropathy.
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